Boston Scientific accounts are for healthcare professionals only.
Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.
My Boston Scientific account
Access your online applications and manage your customer profile.
Quick Links
Call customer care
The Boston Scientific Vercise Genus™ Deep Brain Stimulation System features the first and only FDA-approved 16-contact Vercise™ Cartesia™ X and Cartesia™ HX directional leads, allowing more flexibility in programming. When combined with Image Guided Programming using Illumina 3D™ technology, clinicians can quickly personalize therapy in each patient’s specific anatomy for optimal patient outcomes.
Outcomes matter. Years of research and ongoing clinical studies, including Class 1 randomized control trials and real-world studies, support the efficacy of Boston Scientific’s DBS therapy for patients globally.
Years of science, minutes to program.3 Illumina 3D technology, exclusively from Boston Scientific, leverages intelligent algorithms to enable easy and efficient DBS programming. By generating a patient-specific stimulation plan, Image Guided Programming with Illumina 3D technology provides patients with precise therapy to achieve proven clinical outcomes.
Vercise Cartesia X and Vercise Cartesia HX directional leads offer the best4 in span, spacing and directionality, allowing precise targeting of neural structures.
Boston Scientific’s DBS provides the most therapy options* to personalize patients’ DBS journeys today and in the future.
Monopolar
Bipolar
Bipolar Directional
Demonstrated to improve side-effect thresholds and improve efficacy5,6
Semi-Bipolar
Anodic
Choose from five small, contoured rechargeable and non-rechargeable MR-Conditional** implantable pulse generators (IPGs). Rechargeable options provide 30 days of stimulation between recharging cycles.7 Non-rechargeable options include the Vercise P8 Battery, the only directional single channel primary cell in the market.
*Information for competitive devices excerpted from the literature published by Medtronic (M982261A015 Rev A, M939241A051 Rev A, M013074C001 Rev B, M982097A013 Rev A, M13075C001 Rev B, M019192C002 Rev A) and Abbott (ARTEN600150429 - B, ARTEN600102238 - A, ARTEN600266398 -A, ARTEN600308953 -A, ARTEN600308947 -A), and Schüpbach, Michael & Chabardes, Stephan & Matthies, Cordula & Pollo, Claudio & Steigerwald, Frank & Timmermann, Lars & Vandewalle, Veerle & Volkmann, Jens & Schuurman, P.. (2017). Directional leads for deep brain stimulation: Opportunities and challenges. Movement Disorders. 32. 10.1002/mds.27096. Steffen, J. K., Reker, P., Mennicken, F. K., Dembek, T. A., Dafsari, H. S., Fink, G. R., Visser-Vandewalle, V., & Barbe, M. T. (2020). Bipolar Directional Deep Brain Stimulation in Essential and Parkinsonian Tremor. Neuromodulation: Technology at the Neural Interface, 23(4), 543–549. DOI: 10.1111/ner.13109 Reker, P., Dembek, T. A., Becker, J., Visser-Vandewalle, V., & Timmermann, L. (2016). Directional deep brain stimulation: A case of avoiding dysarthria with bipolar directional current steering. Parkinsonism & Related Disorders, 31, 156-158. https://doi.org/10.1016/j.parkreldis.2016.08.007 Kirsch, A. D., Hassin-Baer, S., Matthies, C., Volkmann, J., & Steigerwald, F. (2018). Anodic versus cathodic neurostimulation of the subthalamic nucleus: A randomized-controlled study of acute clinical effects. Parkinsonism & Related Disorders, 55, 61-67. https://doi.org/10.1016/j.parkreldis.2018.05.015. Boston Scientific (Vercise ™ Neural Navigator 5 Software Programming Manual MP92736308-01)
**MR-Conditional when all conditions of use are met.
